Meet the Team

Managing Director - Steven Trim

Steven Trim has led the company from its incorporation in March 2010 to the respected biotechnology company it is today. Over a decade of experience in pharmaceutical drug discovery means he understands customers' needs better than other venom supply companies around the world. His experience and drive has directly led to many of the company's accolades such as the ELRIG Technology Award (see news section) and opening of the Science Museum's Pain Less exhibition. Steve is a professional associate of the British and Irish Association of Zoos and Aquariums (BIAZA) through his initial pioneering work on safe working practices with venomous arachnids as well as an industrial editor for the Journal of Venom Research.

Financial Director - Clive Newell

Clive has over twenty years' senior financial director experience. He has worked across a range of SME and large corporate clients spanning many industry sectors and is a trusted advisor and leader for many businesses. He has charted a dynamic trajectory from an engineering background on the factory floor to becoming a change agile and innovative finance director. He is also a talented trainer who can impart complex knowledge and information to suit a wide variety of learning preferences.

Scientific Advisor & Non Executive Director - Professor Karol Sikora

Karol Sikora is Medical Director of Cancer Partners UK a group creating the largest independent UK cancer network. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London. He was Director of the WHO Cancer Programme and still advises the WHO and the UN International Atomic Energy Agency. He is Dean and Professor of Medicine at Britain's first independent Medical School at the University of Buckingham and Fellow of Corpus Christi College, Cambridge.

Chairman - Dr Denis Henrard

Denis has over twenty years of international experience in corporate and business development in the pharmaceutical and diagnostic sectors. He has led the identification, valuation and closing of numerous in- and out-licensing deals for large (J&J, Abbott, Becton Dickinson) as well as small biotech companies (Vitex, Elixir, Endotis), primarily in the US. He is also advising emerging healthcare companies in strategic development, operational marketing and partnership negotiations.